Well, if you're going to insist on being That Guy,
Post# of 148175
The DSM*B*, on the other hand, was responsible for observing the study, making sure safety was met and there were signs of efficacy. They made a recommendation to measure mortality past 28 days FOR INTERIM ANALYSIS at 75% ENROLLMENT to TRY TO ESTABLISH HIGHER SIGNIFICANCE IN A SMALLER COHORT.
They NEVER RECOMMENDED adding that TO THE FULL STUDY.
So I would hope CytoDyn does whatever they seem fit, and ignore you and your DSMC... They sound suspect.